mCRP triggers angiogenesis by inducing F3 transcription and TF signalling in microvascular endothelial cells

Summary

Inflammation contributes to vascular disease progression. However, the role of circulating inflammatory molecules on microvascular endothelial cell (mECs) is not fully elucidated. The aim of this study was to investigate the effects of the short pentraxin CRP on microvascular endothelial cell angiogenic function. Subcutaneously implanted collagen plugs seeded with human mECs exposed to monomeric CRP (mCRP) in mice showed formation of an extended network of microvessels both in the plug and the overlying skin tissue, while mECs exposure to pentameric native CRP (nCRP) induced a much milder effect. To understand the mechanisms behind this angiogenic effects, mECs were exposed to both CRP forms and cell migration, wound repair and tube-like formation were investigated. nCRP effects were moderate and of slow-onset whereas mCRP induced rapid, and highly significant effects. We investigated how circulating nCRP is transformed into mCRP by confocal microscopy and western blot. nCRP is transformed into mCRP on the mECs membranes in a time dependent fashion. This transformation is specific and in part receptor dependent, and the formed mCRP triggers F3 gene transcription and TF-protein expression in mECs to induce angiogenesis. F3-silenced mECs are unable to form angiotubes. In agreement, mCRP induced upregulation of the TF signalling pathway in mECs with downstream phosphorylation of AKT and activation of the transcription factor ETS1 leading to increased CCL2 release. The circulating pentraxin nCRP with little pro-angiogenic effect when dissociated into mCRP on the surface of mECs is able to trigger potent proangiogenic effects by inducing F3-gene upregulation and TF signalling.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Tissue factor - angiogenesis - vessel wall remodelling - C-reactive protein - endothelial cells

• References

• 1 Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279: 48487-48490.
• 2 Vilahur G, Badimon L. Biological actions of pentraxins. Vascular Pharmacol 2015; 73: 38-44.
• 3 Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J 2012; 33: 430-432.
• 4 Diehl EE, Haines GK, 3rd Radosevich JA. et al. Immunohistochemical localisation of modified C-reactive protein antigen in normal vascular tissue.. Am J Med Sci 2000; 319: 79-83.
• 5 Rees RF, Gewurz H, Siegel JN. et al. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle.. Clin Immunol Imunopathol 1988; 48: 95-107.
• 6 Krupinski J, Turu MM, Martinez-Gonzalez J. et al. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques.. Stroke 2006; 37: 1200-1204.
• 7 Eisenhardt SU, Habersberger J, Murphy A. et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques.. Circ Res 2009; 105: 128-137.
• 8 Yasojima K, Schwab C, McGeer EG. et al. Generation of C-reactive protein and complement components in atherosclerotic plaques.. Am J Pathol 2001; 158: 1039-1051.
• 9 Turu MM, Slevin M, Matou S. et al. C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression.. BMC Cell Biol 2008; 09: 47.
• 10 Slevin M, Matou-Nasri S, Turu M. et al. Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro.. Brain Pathol 2010; 20: 151-165.
• 11 Carmeliet P. Angiogenesis in health and disease. Nature Med 2003; 09: 653-660.
• 12 Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M. et al. [Neovascularisation in human coronary arteries with lesions of different severity].. Revista Espan Cardiol 2003; 56: 978-986.
• 13 Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293-2300.
• 14 Arderiu G, Pena E, Aledo R. et al. Tissue factor regulates microvessel formation and stabilisation by induction of chaemokine (C-C motif) ligand 2 expression.. Arterioscl Thromb Vasc Biol 2011; 31: 2607-2615.
• 15 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.. Circulation 1997; 95: 594-599.
• 16 Badimon JJ, Lettino M, Toschi V. et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.. Circulation 1999; 99: 1780-1787.
• 17 Wilcox JN, Smith KM, Schwartz SM. et al. Localisation of tissue factor in the normal vessel wall and in the atherosclerotic plaque.. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
• 18 Arderiu G, Pena E, Aledo R. et al. Ets-1 transcription is required in tissue factor driven microvessel formation and stabilisation.. Angiogenesis 2012; 15: 657-669.
• 19 Molins B, Pena E, Vilahur G. et al. C-reactive protein isoforms differ in their effects on thrombus growth.. Arterioscl Thromb Vasc Biol 2008; 28: 2239-2246.
• 20 Molins B, Pena E, de la Torre R. et al. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow.. Cardiovasc Res 2011; 92: 328-337.
• 21 de la Torre R, Pena E, Vilahur G. et al. Monomerisation of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition.. J Thromb Haemost 2013; 11: 2048-2058.
• 22 Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 1998; 30: 1415-1426.
• 23 Ades EW, Candal FJ, Swerlick RA. et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line.. J Invest Dermatol 1992; 99: 683-690.
• 24 Arderiu G, Pena E, Aledo R. et al. Tissue factor-Akt signalling triggers microvessel formation.. J Thromb Haemost 2012; 10: 1895-1905.
• 25 Pena E, Arderiu G, Badimon L. Subcellular localisation of tissue factor and human coronary artery smooth muscle cell migration. J Thromb Haemost 2012; 10: 2373-2382.
• 26 Ferrer-Lorente R, Bejar MT, Tous M. et al. Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: effects on differentiation potential and function.. Diabetologia 2014; 57: 246-256.
• 27 Lugano R, Pena E, Badimon L. et al. Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell.. J Thromb Haemost 2012; 10: 2158-2167.
• 28 Etienne-Manneville S, Hall A. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell 2001; 106: 489-498.
• 29 Hall A. Rho GTPases and the control of cell behavior. Biochem Soc Transact 2005; 33: 891-895.
• 30 Carrio M, Arderiu G, Myers C. et al. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model.. Cancer Res 2005; 65: 7177-7185.
• 31 Molins B, Pena E, Padro T. et al. Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin.. Arterioscl Thromb Vasc Biol 2010; 30: 1246-1252.
• 32 Camino-Lopez S, Llorente-Cortes V, Sendra J. et al. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells.. Cardiovasc Res 2007; 73: 208-216.
• 33 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
• 34 Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005; 04: 3-8.
• 35 Szekanecz Z, Koch AE. Mechanisms of Disease: angiogenesis in inflammatory diseases. Nature Clin Pract Rheumatol 2007; 03: 635-643.
• 36 Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000; 06: 389-395.
• 37 Ridker PM, Danielson E, Fonseca FA. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.. N Engl J Med 2008; 359: 2195-2207.
• 38 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
• 39 Ji SR, Ma L, Bai CJ. et al. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains.. FASEB J 2009; 23: 1806-1816.
• 40 Khreiss T, Jozsef L, Potempa LA. et al. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells.. Circulation 2004; 109: 2016-2022.
• 41 Devaraj S, Du Clos TW, Jialal I. Binding and internalisation of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscl Thromb Vasc Biol 2005; 25: 1359-1363.
• 42 Pasceri V, Cheng JS, Willerson JT. et al. Modulation of C-reactive protein-mediated monocyte chaemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.. Circulation 2001; 103: 2531-2534.
• 43 Verma S, Li SH, Badiwala MV. et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.. Circulation 2002; 105: 1890-1896.
• 44 Wang HW, Sui SF. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Commun 2001; 288: 75-79.
• 45 Bharadwaj D, Stein MP, Volzer M. et al. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II.. The J Exp Med 1999; 190: 585-590.
• 46 Escribano-Burgos M, Lopez-Farre A, del Mar Gonzalez M. et al. Effect of C-reactive protein on Fcgamma receptor II in cultured bovine endothelial cells.. Clin Sci 2005; 108: 85-91.
• 47 Hein TW, Qamirani E, Ren Y. et al. Selective activation of lectin-like oxidized low-density lipoprotein receptor-1 mediates C-reactive protein-evoked endothelial vasodilator dysfunction in coronary arterioles.. Circ Res 2014; 114: 92-100.
• 48 Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscl Thromb Vasc Biol 1995; 15: 612-621.
• 49 Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis 2003; 24: 1009-1013.
• 50 Arderiu G, Espinosa S, Pena E. et al. Monocyte-secreted Wnt5a interacts with FZD5 in microvascular endothelial cells and induces angiogenesis through tissue factor signalling.. J Mol Cell Biol 2014; 06: 380-393.
• 51 Wu J, Stevenson MJ, Brown JM. et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance.. Arterioscl Thromb Vasc Biol 2008; 28: 698-704.
• 52 Cirillo P, Golino P, Calabro P. et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation.. Cardiovasc Res 2005; 68: 47-55.